Neoantigens are newly generated antigens following somatic tumour mutations which confer the immunogenicity of tumour and are necessary for the effectiveness of PD‐1 and PD‐L1 monoclonal antibodies (36). The gene discussed is PDCD1; the disease is neoplasm.